体外膜肺氧合治疗成人暴发性心肌炎的早期疗效及早期预后相关因素
该回顾性病例分析纳入郑州大学第一附属医院2016年11月至2021年5月使用ECMO治疗的38例成人暴发性心肌炎患者,按住院结局分为存活组23例(60.5%)与死亡组15例(39.5%)。结果显示ECMO使用后24 h存活组多项疗效相关生化指标改善优于死亡组,肌酐与肌酸激酶同工酶24 h下降速率快与院内死亡风险降低相关。
要点
- ECMO使用后24 h存活组乳酸、降钙素原、肌酐、转氨酶、CKMB、NT-proBNP水平低于死亡组
- 肌酐24 h下降速率(OR=0.587,95%CI 0.349~0.986,P=0.044)与院内死亡风险降低相关
- CKMB 24 h下降速率(OR=0.177,95%CI 0.037~0.841,P=0.029)与院内死亡风险降低相关
核心结论
- 成人暴发性心肌炎患者早期使用ECMO后24 h,存活组各项疗效相关生化检验指标改善优于死亡组。
- 肌酐和CKMB 24 h下降速率快与使用ECMO治疗后FM患者院内死亡风险降低相关。
研究设计与样本
- 回顾性病例分析研究,纳入2016年11月至2021年5月郑州大学第一附属医院住院并使用ECMO治疗的成年(年龄≥18岁)暴发性心肌炎患者。
- 共纳入38例,按住院期间临床结果分为存活组23例(60.5%)与死亡组15例(39.5%)。
- 采用多因素logistic回归分析院内死亡的影响因素,并比较两组ECMO使用后的并发症情况。
主要发现
- 存活组应用气管插管、肾脏替代治疗的比例和ECMO使用24 h内去甲肾上腺素的用量均低于死亡组(P均<0.05)。
- ECMO使用前两组各项疗效相关生化检验指标差异均无统计学意义(P均>0.05)。
- ECMO使用后24 h,存活组乳酸、降钙素原、肌酐、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、CKMB、N末端B型利钠肽原水平低于死亡组(P均<0.05)。
- 存活组发生中枢出血及急性肾损伤的比例低于死亡组(P均<0.05)。
关键数值与推荐
- 存活组23例(60.5%),年龄(39.6±13.7)岁,女性17例(73.9%),ECMO使用时间(134.4±71.3)h。
- 死亡组15例(39.5%),年龄(40.0±15.8)岁,女性12例(80.0%),ECMO使用时间(120.1±72.4)h。
- 肌酐24 h下降速率与院内死亡风险降低相关:OR=0.587,95%CI 0.349~0.986,P=0.044。
- CKMB 24 h下降速率与院内死亡风险降低相关:OR=0.177,95%CI 0.037~0.841,P=0.029。
临床怎么用
- 对接受ECMO治疗的成人暴发性心肌炎患者,可在上机后24 h复查肌酐与CKMB并计算下降速率,辅助评估院内死亡风险。
- 存活组气管插管、肾脏替代治疗比例及ECMO使用24 h内去甲肾上腺素用量更低,提示早期器官支持负担与预后相关。
局限性
- 本文为单中心回顾性病例分析,样本量38例,结果需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy within the first 24 h post extracorporeal membrane pulmonary oxygenation (ECMO) and the impact of early efficacy on the prognosis of adult patients with fulminant myocarditis (FM). Methods: This retrospective case analysis study included hospitalized patients (age≥18 years) who were diagnosed with fulminant myocarditis from November 2016 to May 2021 in the First Affiliated Hospital of Zhengzhou University. Patients were divided into survival or non-survival groups according to treatment outcomes. The age, sex, treatments, drug use, ECMO use, clinical and laboratory data (before and 24 h after the use of ECMO) were analyzed. The change rate of clinical and laboratory data after 24 h use of ECMO was calculated to find differences between two groups. Multivariate logistic regression was used to analyze the related factors with in-hospital death and complication between the two groups. Results: A total of 38 FM patients treated with ECMO were included. There were 23 cases (60.5%) in the survival group, aged (39.6±13.7) years, and 17 (73.9%) cases were female. The total ECMO time was (134.4±71.3)h. There were 15 cases (39.5%) in non-survival group, aged (40.0±15.8) years, and there were 12(80.0%) female, the ECMO time was (120.1±72.4) h in this group. The proportion of tracheal intubation and continuous renal replacement therapy in the survivor group and dosage of norepinephrine within 24 h after ECMO implantation were significantly less than in non-survival group (all P<0.05). There was no significant difference in all efficacy related biochemical indexes between two groups before ECMO use. The levels of lactic acid, procalcitonin, creatinine, alanine aminotransferase, aspartate aminotransferase, creatine kinase-MB, cardiac troponin I and N-terminal B-type natriuretic peptide prosoma were significantly less in survival group than in non-survival group at 24 h after the use of ECMO (all P<0.05). Results of multivariate logistic regression analysis showed that the higher 24 h change rate of creatinine (OR=0.587, 95%CI 0.349-0.986, P=0.044) and creatine kinase-MB (OR=0.177, 95%CI 0.037-0.841, P=0.029) were positively correlated with reduced risk of in-hospital mortality. The central hemorrhage and acute kidney injury in survival group were less than in non-survivor group (P<0.05). Conclusions: After 24 h early use of ECMO in FM patients, the improvement of various efficacy related biochemical test indexes in the survival group was better than that in the non-survival group. Faster reduction of creatine kinase-MB and creatinine values within 24 h ECMO use is positively correlated with reduced risk of in-hospital mortality in adult patients with FM. 目的: 评估成人暴发性心肌炎(FM)患者使用体外膜肺氧合(ECMO)后24 h的疗效及其对预后的影响。 方法: 本文为回顾性病例分析研究。选取2016年11月至2021年5月于郑州大学第一附属医院住院并使用ECMO治疗的成年FM患者。根据患者住院期间的临床结果将其分为存活组与死亡组。收集并比较两组患者的年龄、性别、治疗情况、药物使用情况、ECMO使用时间及ECMO使用前及使用后24 h的与疗效相关的生化检验指标,并分析生化检验指标的24 h变化速率。采用多因素logistic回归分析FM患者在使用ECMO治疗后发生院内死亡的影响因素,并比较两组在ECMO使用后的并发症情况。 结果: 共纳入使用ECMO治疗的FM患者38例,存活组23例(60.5%),年龄(39.6±13.7)岁,女性17例(73.9%),ECMO使用时间(134.4±71.3)h;死亡组15例(39.5%),年龄(40.0±15.8)岁,女性12例(80.0%),ECMO使用时间(120.1±72.4)h。存活组应用气管插管、肾脏替代治疗的比例和ECMO使用24 h内去甲肾上腺素的用量均低于死亡组(P均<0.05)。ECMO使用前,存活组与死亡组的各项疗效相关生化检验指标差异均无统计学意义(P均>0.05)。ECMO使用后24 h,存活组乳酸、降钙素原、肌酐、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、肌酸激酶同工酶(CKMB)、N末端B型利钠肽原水平低于死亡组(P均<0.05)。多因素logistic回归分析结果显示,肌酐24 h下降速率(OR=0.587,95%CI 0.349~0.986,P=0.044)与CKMB 24 h下降速率(OR=0.177,95%CI 0.037~0.841,P=0.029)与患者院内死亡风险降低相关。并发症方面,存活组发生中枢出血及急性肾损伤的比例低于死亡组(P均<0.05)。 结论: FM患者早期使用ECMO后24 h,存活组的各项疗效相关生化检验指标改善优于死亡组,肌酐和CKMB 24 h下降速率快与使用ECMO治疗后FM患者的院内死亡风险降低相关。.
引用
- Zhou YH, Zhao X, Guo YY, et al. [Early effect of extracorporeal membrane oxygenation and factors related to early outcome in adult patients with fulminant myocarditis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35340146. doi:10.3760/cma.j.cn112148-20210512-00419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。